The average one-year price target for Whitehawk Therapeutics (NasdaqCM:WHWK) has been revised to $6.38 / share. This is an increase of 10.29% from the prior estimate of $5.78 dated April 12, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $8.40 / share. The average price target represents an increase of 53.25% from the latest reported closing price of $4.16 / share.
What is the Fund Sentiment?
There are 49 funds or institutions reporting positions in Whitehawk Therapeutics. This is an decrease of 12 owner(s) or 19.67% in the last quarter. Average portfolio weight of all funds dedicated to WHWK is 0.41%, an increase of 33.54%. Total shares owned by institutions increased in the last three months by 9.87% to 32,160K shares. 
The put/call ratio of WHWK is 1.29, indicating a bearish outlook.
What are Other Shareholders Doing?
QVT Financial holds 4,616K shares representing 9.78% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 4,166K shares representing 8.83% ownership of the company. No change in the last quarter.
Suvretta Capital Management holds 3,700K shares representing 7.84% ownership of the company. No change in the last quarter.
Acuta Capital Partners holds 3,410K shares representing 7.23% ownership of the company. No change in the last quarter.
Avoro Capital Advisors holds 2,849K shares representing 6.04% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
